

Press Release

## Opto Circuits' subsidiary Cardiac Science receives FDA Clearance for MySense Heart®

### Device delivers breakthrough in low-cost, disposable cardiac monitoring

Bengaluru, India | 4 January 2012

Opto Circuits' subsidiary and global leader in automated external defibrillators (AED) and diagnostic cardiac monitoring devices, Cardiac Science Corporation, today announced it has received U. S Food and Drug Administration (FDA) clearance for the sale of **MySense Heart®**, a revolutionary wearable [Holter](#) cardiac monitor.

The device is small, lightweight and disposable, enabling patients to wear it comfortably for an extended time. It's ECG signal quality is superior, facilitating early diagnosis of potentially life-threatening heart diseases. It is also designed to be ultra low-cost, permitting a much broader use of the Holter test in the US and especially emerging markets.

FDA clearance for the product was supported by a robust multi-center clinical trial in the United States and New Zealand conducted in late 2011.

"**MySense Heart®** is yet again a path breaking solution that is designed to manage dynamic challenges of monitoring heart patients. **MySense Heart®** augments our cardiac monitoring suite of products, expanding market addressability and revenues," said Vinod Ramnani, Chairman and Managing Director, Opto Circuits. "We believe **MySense Heart®** provides a clinically relevant economical solution to the healthcare market which hitherto did not exist. It also opens up opportunities for licensing, private labeling and direct-to-consumer retailing."

"**MySense Heart®** is the first in a series of wearable, low-cost monitors being developed at Cardiac Science", said Dave Marver, CSC President and CEO. "We expect to commercially release the product in early 2012 and intend to leverage this revolutionary platform to bring several new products to market."

### About Cardiac Science

Cardiac Science, a wholly owned subsidiary of [Opto Circuits \(India\) Ltd.](#), develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators ([AED](#)), electrocardiograph devices ([ECG/EKG](#)), cardiac [stress treadmill](#) and systems, [PC-based diagnostic workstations](#), [Holter](#) monitoring systems, hospital defibrillators, [vital signs monitors](#), [cardiac rehabilitation](#) telemetry systems, and [cardiology data management](#) systems (informatics) that [connect with hospital information](#) (HIS), [electronic medical record](#) (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted [Burdick®](#), [HeartCentrix®](#), [Powerheart®](#), and [Quinton®](#) brands, is headquartered in Bothell, Washington. With

customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit <http://www.cardiacscience.com>.

## Press Release

### About: [Opto Circuits \(India\) Ltd.](#)

Headquarters: Bengaluru, Karnataka, India  
BSE: 532391 | NSE: OPTOCIRCU

Opto Circuits (India) Ltd. (OCI) is a multinational medtech company in the business of design, development, manufacture and marketing of healthcare equipment and medical interventional products. The product profile includes USFDA-listed, CE-marked cardiac and vital signs monitoring systems, anesthesia and respiratory care equipment, automated external defibrillators, stents, PTA balloons, catheters, body implants and consumables. Some of OCI's well-known brands are [Cardiac Science](#), [Criticare](#), [Eurocor](#), [Ormed](#), [Mediaid](#) and [Unetixs](#). The company's key markets are North America, Europe and BRIC countries.

### Contact

Opto Circuits: Anna Beck (+91 8105674545) / Nidhi Thind (+91 9591994196) | E: [media@optoindia.com](mailto:media@optoindia.com)

Adfactors PR: Neha Goenka (+91 22 22813565) | E: [neha.goenka@adfactorspr.com](mailto:neha.goenka@adfactorspr.com)

#####